No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 160 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR The Caregiver Curve March 15, 2021 7 ways we’ve influenced progress in lung cancer November 1, 2022 Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow April 12, 2023 How I Learned to Cope With Survivor’s Guilt After Cancer January 27, 2021 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Durvalumab to Patients with... Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with... Smoking among young adults increased by 25% during first lockdown Looking back at a life-changing clinical trial
